-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In a new study, researchers found that certain neurogenesia factors in people with depression or bipolar disorder were lower than in healthy people.
this provides a basis for future use of growth factor levels to monitor the effectiveness of antidepressant therapy, the paper was published in January 2021 in Journal of Psychiatric Research.
previous studies have shown lower levels of brain-based neurotrophic factors (BDNF) in the blood of people with mood disorders.
, little is known about changes in BDNF and its pre-proBDNF in lymphocytes.
addition, early studies using commercial ELISA kits were unable to distinguish between mature BDNF and proBDNF.
this study aims to study changes in the levels of exosymetic mBDNF and proBDNF and their diagnostic value for mood disorders using specific enzyme-linked immunosorption tests (ELISA).
results showed a significant decrease in serum mBDNF levels in the severe depression (MDD) group (n-90) and bipolar disorder (BD) group (n-15), while there was no significant change in the suicide group (n-14) compared to the control group (n-96).
in the MDD subgroup, the serum mBDNF level of severe MDD patients was significantly lower than that of moderate MDD patients (P.lt;05).
serum mBDNF levels in the group without antidepressants were significantly lower than in the treatment group .
results suggest that serum mBDNF has good diagnostic value for MDD and BD, sensitivity and specificity in about 80-83%.
levels of lymphocyte mBDNF, proBDNF and their sotilin proteins in patients with MDD were significantly higher than those of the control group.
specific ELISA tests of mature BDNF confirmed a decrease in serum mBDNF levels in patients with MDD and BD, indicating that patients' blood mBDNF levels could be used as a potential indicator for diagnosing MDD with a critical value of 12.4 ng/ml, so the researchers believe that the increase in lymphocyte proBDNF and mBDNF in MDD patients can be used as a new pathological marker of MDD.
